Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

Abstract

The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer

1 - 21 . (canceled) 
     
     
         22 . A tablet comprising: 
       
         
           
                 
                 
               
                     
                 
                   3 mg 
                   N-(3,5-dimethoxyphenyl)-N′-(1- 
                 
                     
                   methylethyl)-N-[3-(1-methyl-1H-pyrazol- 
                 
                     
                   4-yl)quinoxalin-6-yl]ethane-1,2-diamine; 
                 
                   1.5 mg 
                   meglumine; 
                 
                   from 20% to 95% w/w 
                   mannitol; 
                 
                   from 20% to 95% w/w 
                   microcrystalline cellulose; 
                 
                   from 2.5 to 5% w/w 
                   croscarmellose sodium; and 
                 
                   from 0.5 to 1.5% w/w 
                   magnesium stearate. 
                 
                     
                 
             
                
               
               
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         23 . The tablet of  claim 22 , wherein the total weight of the tablet is about 150 mg. 
     
     
         24 . A tablet comprising: 
       
         
           
                 
                 
               
                     
                 
                   4 mg 
                   N-(3,5-dimethoxyphenyl)-N′-(1- 
                 
                     
                   methylethyl)-N-[3-(1-methyl-1H-pyrazol- 
                 
                     
                   4-y1)quinoxalin-6-yl]ethane-1,2-diamine; 
                 
                   2 mg 
                   meglumine; 
                 
                   from 20% to 95% w/w 
                   mannitol; 
                 
                   from 20% to 95% w/w 
                   microcrystalline cellulose; 
                 
                   from 2.5 to 5% w/w 
                   croscarmellose sodium; and 
                 
                   from 0.5 to 1.5% w/w 
                   magnesium stearate. 
                 
                     
                 
             
                
               
               
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         25 . The tablet of  claim 24 , wherein the total weight of the tablet is about 200 mg. 
     
     
         26 . A tablet comprising: 
       
         
           
                 
                 
               
                     
                 
                   5 mg 
                   N-(3,5-dimethoxyphenyl)-N′-(1- 
                 
                     
                   methylethyl)-N-[3-(1-methyl-1H-pyrazol- 
                 
                     
                   4-yl)quinoxalin-6-yl]ethane-1,2-diamine; 
                 
                   2.5 mg 
                   meglumine; 
                 
                   from 20% to 95% w/w 
                   mannitol; 
                 
                   from 20% to 95% w/w 
                   microcrystalline cellulose; 
                 
                   from 2.5 to 5% w/w 
                   croscarmellose sodium; and 
                 
                   from 0.5 to 1.5% w/w 
                   magnesium stearate. 
                 
                     
                 
             
                
               
               
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         27 . The tablet of  claim 26 , wherein the total weight of the tablet is about 250 mg.